Partial Nephrectomy for Metastatic Renal Cell Carcinoma: Pro.
作者信息
Campbell Steven C, Ornstein Moshe C, Rathi Nityam
机构信息
Department of Urology, Cleveland Clinic, Cleveland, OH, USA.
Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH, USA.
出版信息
Eur Urol Open Sci. 2022 Aug 30;44:92-93. doi: 10.1016/j.euros.2022.05.019. eCollection 2022 Oct.
Abstract
摘要
相似文献
1
Partial Nephrectomy for Metastatic Renal Cell Carcinoma: Pro.转移性肾细胞癌的部分肾切除术：专家意见
Eur Urol Open Sci. 2022 Aug 30;44:92-93. doi: 10.1016/j.euros.2022.05.019. eCollection 2022 Oct.
2
Partial nephrectomy in the setting of metastatic renal cell carcinoma.转移性肾细胞癌背景下的部分肾切除术。
J Urol. 2014 Jul;192(1):36-42. doi: 10.1016/j.juro.2014.01.086. Epub 2014 Feb 8.
3
Partial nephrectomy versus radical nephrectomy for non-metastatic pathological T3a renal cell carcinoma: a multi-institutional comparative analysis.部分肾切除术与根治性肾切除术治疗非转移性 T3a 期肾细胞癌：多机构比较分析。
Int J Urol. 2014 Apr;21(4):352-7. doi: 10.1111/iju.12283. Epub 2013 Sep 30.
4
Is there a role for partial nephrectomy in patients with metastatic renal cell carcinoma?部分肾切除术在转移性肾细胞癌患者中的作用如何？
Urol Oncol. 2013 Jan;31(1):36-41. doi: 10.1016/j.urolonc.2010.08.026. Epub 2011 Mar 10.
5
Management of locally recurrent renal cell carcinoma after partial nephrectomy.肾部分切除术后局部复发性肾细胞癌的管理
J Urol. 1987 Sep;138(3):607-10. doi: 10.1016/s0022-5347(17)43273-3.
6
Role of partial nephrectomy as cytoreduction in the management of metastatic renal cell carcinoma.部分肾切除术作为减瘤手术在转移性肾细胞癌治疗中的作用
Minerva Urol Nefrol. 2015 Jun;67(2):149-56. Epub 2015 Feb 3.
7
Complete remission of renal cell carcinoma with lung carcinomatous lymphangiosis after primary therapy with immune checkpoint inhibitors followed by partial nephrectomy for surgical consolidation.经免疫检查点抑制剂初始治疗后肾细胞癌合并肺癌性淋巴管炎完全缓解，随后行部分肾切除术进行手术巩固治疗。
IJU Case Rep. 2022 Mar 25;5(3):168-171. doi: 10.1002/iju5.12427. eCollection 2022 May.
8
Cytoreductive Nephrectomy Following Immunotherapy-Base Treatment in Metastatic Renal Cell Carcinoma: A Case Series and Review of Current Literature.免疫治疗基础治疗后行细胞减积性肾切除术治疗转移性肾细胞癌：病例系列及文献复习。
Curr Oncol. 2021 May 20;28(3):1921-1926. doi: 10.3390/curroncol28030178.
9
A Phase II Study of Pazopanib in Patients with Localized Renal Cell Carcinoma to Optimize Preservation of Renal Parenchyma.帕唑帕尼治疗局限性肾细胞癌以优化保留肾实质的 II 期研究。
J Urol. 2015 Aug;194(2):297-303. doi: 10.1016/j.juro.2015.03.096. Epub 2015 Mar 23.
10
The Effect of Cytoreductive Partial Nephrectomy in Elderly Patients with Metastatic Renal Cell Carcinoma.细胞减灭性部分肾切除术对转移性肾细胞癌老年患者的影响。
Clin Interv Aging. 2020 Mar 20;15:431-439. doi: 10.2147/CIA.S243902. eCollection 2020.
引用本文的文献
1
Partial Nephrectomy for Metastatic Renal Cell Carcinoma: Referee.转移性肾细胞癌的部分肾切除术：评审意见
Eur Urol Open Sci. 2022 Aug 30;44:78-80. doi: 10.1016/j.euros.2022.08.007. eCollection 2022 Oct.
本文引用的文献
1
Nivolumab, nivolumab-ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial.纳武利尤单抗、纳武利尤单抗-伊匹木单抗和VEGFR酪氨酸激酶抑制剂作为转移性透明细胞肾细胞癌的一线治疗（BIONIKK）：一项生物标志物驱动、开放标签、非对照、随机2期试验。
Lancet Oncol. 2022 May;23(5):612-624. doi: 10.1016/S1470-2045(22)00128-0. Epub 2022 Apr 4.
2
Clinical Review on the Management of Metastatic Renal Cell Carcinoma.转移性肾细胞癌管理的临床综述
JCO Oncol Pract. 2022 Mar;18(3):187-196. doi: 10.1200/OP.21.00419. Epub 2021 Sep 16.
3
Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma.肾细胞癌肾切除术后辅助帕博利珠单抗。
N Engl J Med. 2021 Aug 19;385(8):683-694. doi: 10.1056/NEJMoa2106391.
4
Sunitinib Alone or After Nephrectomy for Patients with Metastatic Renal Cell Carcinoma: Is There Still a Role for Cytoreductive Nephrectomy?舒尼替尼单药治疗或肾切除术治疗转移性肾细胞癌患者：细胞减积性肾切除术是否仍有作用？
Eur Urol. 2021 Oct;80(4):417-424. doi: 10.1016/j.eururo.2021.06.009. Epub 2021 Jun 27.
5
Renal Mass and Localized Renal Cancer: Evaluation, Management, and Follow-Up: AUA Guideline: Part I.肾脏肿块和局限性肾细胞癌：评估、管理和随访：AUA 指南：第 1 部分。
J Urol. 2021 Aug;206(2):199-208. doi: 10.1097/JU.0000000000001911. Epub 2021 Jul 11.
6
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.仑伐替尼联合帕博利珠单抗或依维莫司治疗晚期肾细胞癌。
N Engl J Med. 2021 Apr 8;384(14):1289-1300. doi: 10.1056/NEJMoa2035716. Epub 2021 Feb 13.
7
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial.纳武利尤单抗联合伊匹木单抗与舒尼替尼一线治疗晚期肾细胞癌：III期CheckMate 214试验的4年延长随访
ESMO Open. 2020 Nov;5(6):e001079. doi: 10.1136/esmoopen-2020-001079.
8
Optimizing patient selection for cytoreductive nephrectomy based on outcomes in the contemporary era of systemic therapy.基于系统治疗时代的结果优化细胞减灭性肾切除术的患者选择。
Cancer. 2020 Sep 1;126(17):3950-3960. doi: 10.1002/cncr.32991. Epub 2020 Jun 9.
9
Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial.舒尼替尼治疗同步转移性肾细胞癌患者中即刻与延迟细胞减瘤性肾切除术的比较：SURTIME 随机临床试验。
JAMA Oncol. 2019 Feb 1;5(2):164-170. doi: 10.1001/jamaoncol.2018.5543.
10
Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma.系统评价细胞减积性肾切除术在靶向治疗时代及以后的作用：转移性肾细胞癌的个体化治疗方法。
Eur Urol. 2019 Jan;75(1):111-128. doi: 10.1016/j.eururo.2018.09.016. Epub 2018 Oct 25.
Zotero 插件